Related Experiment Video

Updated: Feb 20, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

6.0K

High-dose atorvastatin reduces the risk of cardiovascular events in patients with percutaneous coronary intervention

Changqing Lu1, Helei Jia1, Zhentao Wang2

  • 1Department of Emergency, Henan Province Hospital of Traditional Chinese Medicine, Zhengzhou, Henan Province 450002, China.

Oncotarget
|October 21, 2017
PubMed

Insights

High-dose Atorvastatin significantly reduces myocardial infarction and adverse cardiovascular events in patients undergoing percutaneous coronary intervention. This meta-analysis recommends high-dose Atorvastatin as an adjunct therapy for PCI patients.

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Trials

Background:

  • Percutaneous coronary intervention (PCI) is a common procedure for coronary artery disease.
  • Statins, particularly high-dose Atorvastatin, are frequently used to manage cardiovascular risk.
  • Optimizing adjunctive therapies for PCI remains crucial for improving patient outcomes.

Purpose of the Study:

  • To systematically evaluate the efficacy of high-dose Atorvastatin in patients undergoing PCI.
  • To assess the impact of high-dose Atorvastatin on myocardial infarction and adverse cardiovascular events.
  • To determine if high-dose Atorvastatin is a beneficial adjunct therapy for PCI.

Main Methods:

  • A meta-analysis of 12 randomized controlled trials involving 2801 patients.
  • Searches conducted in PubMed, Web of Science, Embase, and China National Knowledge Infrastructure.
  • Statistical analysis included fixed-effect models and trial sequential analysis to assess efficacy and heterogeneity.

Main Results:

  • High-dose Atorvastatin significantly reduced the risk of myocardial infarction (RR=0.62, 95% CI: 0.49-0.78) with low heterogeneity (I²=22.6%).
  • Adverse cardiovascular events were reduced by 65% (RR=0.65, 95% CI: 0.50-0.84), confirmed by trial sequential analysis.
  • Subgroup analyses and publication bias tests (Egger's and Begg's) supported the findings.

Conclusions:

  • High-dose Atorvastatin effectively reduces the risk of myocardial infarction and adverse cardiovascular events in patients undergoing PCI.
  • The findings support the recommendation of high-dose Atorvastatin as an adjunct therapy to PCI.
  • Further research may explore optimal dosing strategies and long-term outcomes.

Keywords:
atorvastatininterventionmeta-analysispercutaneous coronary interventionrandomized controlled trials

More Related Videos

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis04:30

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

26.4K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

15.1K

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
465
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.5K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
741
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
320
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
388
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
330